Bellevue Asset Management (Switzerland)’s Acadia Pharmaceuticals ACAD Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.6M	Sell	45,000 -14,000	-24%	-$493K	0.24%	93
2015 Q3	$1.95M	Sell	59,000 -42,000	-42%	-$1.75M	0.32%	85
2015 Q2	$4.23M	Sell	101,000 -130,000	-56%	-$5.03M	0.59%	58
2015 Q1	$7.53M	Buy	+231,000	New	+$7.94M	1.05%	34

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ACAD Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Acadia Pharmaceuticals (ACAD) stake by 24% in Q4 2015, selling an estimated $493K and leaving 45,000 shares worth $1.6M. The position accounts for 0.24% of the portfolio, ranked #93.

Bellevue Asset Management (Switzerland) first reported a position in ACAD in Q1 2015 and has held it in 4 quarters since. The position peaked at $7.53M in Q1 2015. 215 funds tracked by Wall St. Rank hold ACAD as of Q4 2015.

Bellevue Asset Management (Switzerland) held 45,000 shares of Acadia Pharmaceuticals worth $1.6M as of Q4 2015.
Bellevue Asset Management (Switzerland) sold 14,000 Acadia Pharmaceuticals shares in Q4 2015, an estimated $493K.
Acadia Pharmaceuticals made up 0.24% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #93 holding.
Bellevue Asset Management (Switzerland) first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
Bellevue Asset Management (Switzerland)'s Acadia Pharmaceuticals position peaked at $7.53M in Q1 2015.
215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.